UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (State ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Conference Call Participants Welcome to the Lineage Cell Therapeutics First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors section of Lineage 's website at www.lineage cell.com. This call is subject to copyright and is property of Lineage and recordings, reproductions, or transmissions of this call without the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (Stat ...

Company Participants Conference Call Participants Operator I would now like to introduce you to the host for today's call, Ioana Hone, Head of Investor Relations at Lineage . Ms. Hone, please go ahead. Thanks, Mandeep. Good afternoon and thank you for joining us. A press release reporting our fourth quarter and full year 2022 financial results was issued earlier today, March 9, 2023, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (State ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO and Interim CFO Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants William Wood - B. Riley Securities Rick Miller - Cantor Fitzgerald Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. An aud ...

Start Time: 16:30 January 1, 0000 5:18 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 PM ET Company Participants Brian Culley - CEO and Interim CFO Gary Hogge - SVP, Clinical and Medical Affairs Ioana Hone - Head of IR Conference Call Participants William Wood - B. Riley Securities Rick Miller - Cantor Fitzgerald Joe Pantginis - H.C. Wainwright Jason McCarthy - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Second Quarter 2022 Confer ...

== L I N E A G E The future of cell therapy. Corporate Overview April 25, 2022 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and there can be no assurance a ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Brian Culley – Chief Executive Officer Gary Hogge – SVP, Clinical and Medical Affairs Ioana Hone – Director of Investor Relations Conference Call Participants Joe Pantginis – H.C. Wainwright & Co., LLC Kristen Kluska – Cantor Fitzgerald Jason McCarthy – Maxim Group, LLC William Wood – B. Riley Securities Robert LeBoyer – Noble Capital Markets Operator Welcome to the Lineage Cell Therapeu ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2021 Results Conference Call March 10, 2022 4:30 PM ET Company Participants Ioana Hone - Head, IR Brian Culley - CEO Kevin Cook - CFO Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants Kristen Kluska - Cantor Fitzgerald Joe Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Robert LeBoyer - Noble Capital Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2021 Conference Call. At this time, all parti ...